

Name	Date of declaration	Project element	Specific Personal Financial	Specific Personal non-financial	Specific non-personal financial	Specific non-personal non-financial	Non-specific Personal Financial	Non-specific Personal Non-financial	Non-specific non-personal financial	Non-specific non-personal non-financial
			<p>hybrid closed loop/artificial pancreas systems, including the CamAPS FX system developed at the University of Cambridge</p> <p>Medtronic payed to exhibit at our events (Fusion and Discovery Days)</p> <p>Dexcom paid to exhibit at our events (Discovery Days and Fusion), partner in our Pathway to Choice initiative, advertise in our publications</p> <p>Tandem paid to exhibit at our events (Fusion and Discovery Days)</p>							

Name	Date of declaration	Project element	Specific Personal Financial	Specific Personal non-financial	Specific non-personal financial	Specific non-personal non-financial	Non-specific Personal Financial	Non-specific Personal Non-financial	Non-specific non-personal financial	Non-specific non-personal non-financial
			<p>Dana paid to exhibit at two Fusion events in 2021</p> <p>Insulet paid to exhibit at our events (Discovery Days and Fusion), partner in our Pathway to Choice initiative, advertise in our publications</p> <p>Companies exhibited technologies which included component parts of closed loop systems</p>							
Ian Phillip Craigie	04/10/2021	Peer-review; Consultation	None	None	None	None	None	None	None	None
Jeff Foot	01/10/2021	Peer-review	None	NICE - Specialist Lay Member of committee assessing Closed Loop Systems and Artificial Pancreas in management	Has a relevant health condition	None	None	None	None	None

Name	Date of declaration	Project element	Specific Personal Financial	Specific Personal non-financial	Specific non-personal financial	Specific non-personal non-financial	Non-specific Personal Financial	Non-specific Personal Non-financial	Non-specific non-personal financial	Non-specific non-personal non-financial
				of Type 1 Diabetes						
Shareen Forbes	03/10/2021	Peer-review	None	Diabetes UK – Clinical Studies Group 2 - Causes and prevention of type I diabetes (Group of HCPs and people with Type 1 diabetes) [Discussions include closed loop systems]	Helmsley automated delivery system – Helmsley Foundation funded research on closed loop system Royal College of Surgeons Clinical – supervision of a Research Fellow on insulin delivery and retinopathy (ceased 01/12/2020) – some insulin delivery by closed loop system	None	Novo Nordisk consultancy on islet transplantation Novo Nordisk grant on islet transplantation – awarded to declarer CSO, MRC, MRS – islet transplantation – PI or CI for all – grant funded – supervising students performing research Scottish National blood transfusion service – cell therapy products - PI or CI for all – grant funded – supervising students performing research	Novo Nordisk UK Foundation board of trustees, [Novo Nordisk UK Research Foundation is an independent registered charity that supports research and education in diabetes and provides clinical research awards.] Member of the JDRF scientific council, Society for Endocrinology (x2) – member of council and lead metabolic and obesity network	None	Employed at University of Edinburgh – supervisions of staff including fellow - Automated Insulin Delivery – conducting research study currently – devices tested include Dexcom & Tandem
Fraser Gibb	29/09/2021	Peer-review; Presented at Council	None	None	None	None	Lilly Diabetes, Speaker & Novo Nordisk,	None	None	None

Name	Date of declaration	Project element	Specific Personal Financial	Specific Personal non-financial	Specific non-personal financial	Specific non-personal non-financial	Non-specific Personal Financial	Non-specific Personal Non-financial	Non-specific non-personal financial	Non-specific non-personal non-financial
							Speaker (topic: insulins) Abbott Diabetes, Speaker/Consultant Fees			
Andrew Gallagher	04/10/2021	Peer-review; Consultation	None	None	None	None	None	None	None	None
Alison Grant (Diabetes UK)	01/10/2021	Peer-review	None	None	None	None	None	None	None	None
Fiona Green	16/11/2021		None	None	None	None	None	None	None	None
Brian Kennon [Waiver]	20/08/21	Peer-review; Presented at Council	None	Scottish Government Chair of Scottish Diabetes Group and author Diabetes Improvement Plan: highlights a priority to improve access to diabetes technologies	None	None	Lily Speaker fee for meeting in Sep 2021 [update from SG on Diabetes Improvement Plan]	None	Thermidas Project Manager funding for foot project [dept funding for thermography in diabetes foot]	None
Robert Lindsay	30/09/2021	Peer-review	None	CamAps/ Advanced Therapeutics PI for multicentre study of use of CamAps in pregnancy (Cl Murphy) SBK Healthcare	None	None	Dexcom - Application to company for small grant funding to collate CGM data from pregnancy	None	None	None

Name	Date of declaration	Project element	Specific Personal Financial	Specific Personal non-financial	Specific non-personal financial	Specific non-personal non-financial	Non-specific Personal Financial	Non-specific Personal Non-financial	Non-specific non-personal financial	Non-specific non-personal non-financial
				Talk on closed loop in pregnancy at Diabetes Closed Loop Technology Scottish Regional Forum (ceased 21/09/21)						
Theresa Marshall	14/10/2021	Peer-review	Shares in Medtronic;	None	None	None	Employee of Medtronic Ltd			
Rory McCrimmon	15/11/21	Consultation	None	None	None	None	Sanofi consultancy fees NovoNordisk consultancy fees (both companies produce insulin)	None	None	None
Joan McDowell	09/10/2021	Peer-review	None	None	None	None	Shares in: AstraZeneca, Clinigen, Glaxo Smith Kline, Smith & Nephew Practical Diabetes journal, Co-editor	None	None	None
David McGrane	04/10/2021	Peer-review; Consultation	None	None	None	None	None	None	None	None
Sandra McRury	30/09/2021	Peer-review	None	None	None	None	None	None	SEUPB, Interreg Grant & ESA, UK Grant	None

Name	Date of declaration	Project element	Specific Personal Financial	Specific Personal non-financial	Specific non-personal financial	Specific non-personal non-financial	Non-specific Personal Financial	Non-specific Personal Non-financial	Non-specific non-personal financial	Non-specific non-personal non-financial
Joel Milner (iPAG Scotland)	01/10/2021	Peer-review	Advanced Therapeutics Ltd Grant – Registration Fee for ATTD conference Feb 2019 Grant - Registration Fee for ATTD conference Feb 2020 [some presentations on CLS at events attended by declarer]	IPAG Scotland Member of Committee (Secretary) – unpaid position – includes promoting access to CLS	None	None	None	None	None	None
Mary Moody [iPAG]	01/10/2021	Peer-review; Presented at Council	None	None	None	None	None	IPAG Scotland Chair of Committee	None	None
Liz Perraudin (Diabetes UK)	22/11/2021	Presented at council	None	Living with type 1 diabetes	Diabetes UK receives funding from a range of pharmaceutical and medical technology companies. The income we receive from these companies represents 6% of Diabetes UK's total income.	Diabetes UK advocates for improved access to diabetes technologies, including hybrid closed-loop technology. We have published position statements about open-source closed-loop technology and have	None	None	None	None

Name	Date of declaration	Project element	Specific Personal Financial	Specific Personal non-financial	Specific non-personal financial	Specific non-personal non-financial	Non-specific Personal Financial	Non-specific Personal Non-financial	Non-specific non-personal financial	Non-specific non-personal non-financial
					Diabetes UK (declarer is member of this team) does not receive any direct or ring fenced funding from any pharmaceutical or medtech industry companies.	outlined our position on hybrid-closed loop technology in media statements and reports which can be found on our website. CamAPS - Diabetes UK funded research into this hybrid closed-loop technology. This funding was separate from any of our policy work in this area.				
Sam Philip	01/10/2021	Peer-review	None	None	None	None	NAPP pharmaceutical, Sanofi, Eli-Lilly speaker fees [Topics: medical management of type 2 diabetes or SCI-diabetes] Novo Nordisk, Sanofi, Eli-Lilly clinical trials [PI for trials on	None	None	None

